Blood group genotyping by DNA array contributes to the management of transfusions in SCD patients by facilitating the transfusion support with antigen-matched blood. It has the potential to improve the life of thousands of SCD-transfused patients by reducing mortality due to transfusion reactions and immunization.

DNA typing of blood groups by PCR-RFLP in peripheral blood WBCs contributes to the management of transfusions in SCD patients by allowing a more accurate selection of donor units.

The GATA box single nucleotide polymorphism (SNP) at position -33 (T>C) in Blacks silences the expression of FY*B in erythrocytes, and the substitution 265 C>T, together with 298 G>A, weakens the Fy(b) antigen (Fy(x)). Individuals with these phenotypes/genotypes who receive Fy(b+) blood are unlikely to be alloimmunized to Fy(b) because, in the presence of 265 T, the Fy(b) antigen is expressed, and in the case of -33 C, other tissues express Duffy protein and probably the Fy(b) antigen. We studied samples from 361 blood donors (182 of African ancestry and 179 of Caucasian ancestry) by haemagglutination and polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP). Forty Caucasian and 130 donors of African ancestry were serologically Fy(b-); among these, the majority of the donors of African ancestry had FY*B with the GATA SNP, while the majority of Caucasians typing Fy(b-) had FY*B with 265 T/298 A SNPs. Six of the Fy(b-) donors (three Africans and three Caucasians) had both GATA and 265/298 SNPs, and six donors of Caucasian ancestry apparently had a GATA SNP. Samples from two donors - one African and one Caucasian with an unusual MspA1I-RFLP pattern - were sequenced and found to have a novel SNP (145 G>T) co-existent with 265 C>T and 298 G>A SNPs. These findings highlight the importance of establishing the incidence and nature of molecular events that impact on Duffy expression in different populations.

We have set out to determine the frequency of DIIIa and DAR alleles among sickle cell disease (SCD) patients. These D variants permit the unexpected development of antibodies to RhD among individuals who are otherwise classified as RhD+. DNA samples from 130 SCD patients were tested for 455A>C (specific for DIIIa), 602C>G, 667T>G (common for both DIIIa and DAR) and 1025T>C (specific for DAR) by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and sequence analysis. The PCR-RFLP showed that 12 (9.2%) of the SCD patients were carrying DIIIa and DAR alleles. Genomic DNA analysis performed by sequence showed that three samples were heterozygous DIIIa (2.3%), seven heterozygous DAR (4.6%) and two (1.5%) samples carried a partial D with four mutations: 455A>C (heterozygous), 602C>G and 667T>G (homozygous) and 1025T>C (heterozygous), indicating compound heterozygosity for one DIIIa allele and one DAR allele. The predicted phenotypes of eight (6.2%) SCD patients were DIIIa, DAR and DIIIa/DAR. Three patients were anti-D immunized (DAR, n = 1; DIIIa/DAR, n = 2). These findings suggest that SCD patients who are candidates for chronic transfusion may benefit from genotyping for DIIIa and DAR to prevent alloimmunization.